Results 21 to 30 of about 9,123 (152)

Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients. [PDF]

Clin Transl Sci
ABSTRACT Interpatient variability in tacrolimus pharmacokinetics is due in part to variation in metabolism by cytochrome P‐450 3A5 and 3A4 and membrane transport by P‐glycoprotein. We evaluated the combined role CYP3A5*3 and CYP3A4*1B genotypes have on tacrolimus pharmacokinetics in 65 stable Black and White kidney transplant recipients receiving ...
Brazeau D, Attwood K, Cooper LM, Gray V, Chang S, Chen S, Murray BM, Tornatore KM.   +7 more
europepmc   +2 more sources

Eficácia terapêutica do Tacrolimo em pacientes pós-transplante hepático com polimorfismos genéticos do citocromo P450 3A5 (CYP3A5)

Revista do Colégio Brasileiro de Cirurgiões
RESUMO Os polimorfismos genéticos do CYP3A5 têm sido apontados enquanto fatores influenciadores na eficácia farmacológica com tacrolimo em pacientes em terapia imunossupressora no pós-transplante hepático.
Lucas Soares Bezerra, Marcelo Antônio Oliveira Santos-Veloso, Saulo Bruno Lopes de Oliveira, Anderson André Pantoja Dias, Ângelo Teles de Carvalho-Filho, Pedro Pereira Gonzaga-Neto, Paulo Sérgio Vieira de Melo   +6 more
doaj   +1 more source

Cell type-specific expression and localization of cytochrome P450 isoforms in tridimensional aggregating rat brain cell cultures. [PDF]

, 2015
Within the Predict-IV FP7 project a strategy for measurement of in vitro biokinetics was developed, requiring the characterization of the cellular model used, especially regarding biotransformation, which frequently depends on cytochrome P450 (CYP ...
Gemma, S., Kopp-Schneider, A., Monnet-Tschudi, F., Sandström von Tobel, J., Stanzel, S., Testai, E., Vichi, S., Zurich, M.G.   +7 more
core   +1 more source

Current trends in drug metabolism and pharmacokinetics. [PDF]

, 2019
Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication.
Abduljalil, Aghazadeh-Habashi, Aigrain, Aitman, Al Za'abi, Alegre, Alnaqeeb, Aspromonte, Babiskin, Baert, Bakke, Barnett, Bhattacharyya, Cang, Cannady, Cao, Cao, Capecchi, Chen, Chen, Chen, Chen, Chen, Chen, Chen, Cheng, Cheng, Crawford, Currie, De Lange, Dean, Deng, Di Paolo, Dietrich, Diliberto, Dluzen, Dowling, Dragin, Dreisbach, Duan, Edeogu, Edginton, El-Arabey, El-Kadi, EMA, Eum, Falany, Fang, FDA, Feng, Feng, Feng, Ferri, Fleming, Foti, Fox, Freedman, Frye, Fukami, Gaj, Gan, Gao, Gao, Gao, Gao, Gao, Ge, Genovese, Gingell, Gingell, Gong, Graham, Gufford, Guo, Guo, Guo, Guévin, Han, Harrison, Hartz, Hasegawa, He, He, He, He, He, Ho, Ho, Hou, Hsu, Hsueh, Hu, Hu, Hu, Huo, Hwang, Ito, Jacob, Jeong, Jeong, Jia, Jian, Jiang, Jiang, Jiang, Jiang, Jilek, Jilek, Johnson, Jorga, Jung, Kaivosaari, Kalthoff, Kaminsky, Kannan, Karibe, Kesisoglou, Kim, Kim, Knights, Kong, Kota, Kumar, Kurokawa, Lai, Lan, Lanchote, Lee, Lehouritis, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Liang, Lin, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Lopes-Rodrigues, Lu, Lu, Lu, Löfgren, Mano, Marchitti, Margolskee, Martin, Matsson, Mattick, Mazerska, Mei, Mencia, Meng, Min, Mitra, Miyajima, Müller, Nair, Nakano, Nakano, Nakano, Nebert, Nguyen, Niederalt, Nieto Montesinos, Niu, Notenboom, Nozaki, Ohtsuki, Ono, Oostendorp, Pan, Pan, Papageorgiou, Papageorgiou, Park, Pea, Pedersen, Pelkonen, Pellegrino, Pettersson Bergstrand, Qi, Qin, Qiu, Qiu, Raaska, Rives, Riviere, Roberts, Robey, Rocha, Rose, Routy, Rowland, Ruwali, Saini, Satoh, Savage, Scheer, Scheer, Schlender, Schmitt, Schneider, Seitz, Showande, Shu, Shu, Shu, Shugarts, Siu, Song, Staudinger, Strong, Suarez-Sharp, Suh, Suiko, Sukkummee, Sun, Sun, Sutliff, Takeda, Tan, Tan, Tao, Tatsumi, Teorell, Tsai, Tsang, Tsuchiya, Tsume, Tu, Ulldemolins, van Waterschoot, von Richter, Vugmeyster, Vuppugalla, Wagner, Wagner, Wagner, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wassenaar, Watanabe, Wei, Wijayakumara, Wilkinson, Wong, Wu, Xia, Xie, Xie, Xu, Xu, Xu, Xu, Xu, Xue, Yamagata, Yamaguchi, Yan, Yang, Yang, Yang, Ye, Yellepeddi, Yi, Yi, Yigitaslan, Yim, Yin, Yoshida, Yoshida, Yoshimi, Yu, Yu, Yu, Yu, Yu, Yu, Yu, Zakeri-Milani, Zanger, Zeng, Zeng, Zhai, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhao, Zhao, Zhao, Zhao, Zhou, Zhou, Zhou, Zhou, Zhou, Zhu, Zhu, Zhu, Zhuang, Zimmermann   +332 more
core   +1 more source

Porcine foetal and neonatal CYP3A liver expression [PDF]

, 2011
Human cytochrome P450 3A7 (CYP3A7) and cytochrome P450 3A4 (CYP3A4) are hepatic metabolising enzymes which participates in the biotransformation of endo- and exogenous substances in foetuses and neonates respectively.
Hermann-Bank, Marie Louise, Skaanild, Mette Tingleff   +1 more
core   +2 more sources

Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults [PDF]

, 2017
Background The clearance of cytochrome P450 (CYP) 3A substrates is reported to be reduced with lower age, inflammation and obesity. As it is unknown what the overall influence is of these factors in the case of obese adolescents vs.
Anker, J.N. (John) van den, Barrett, J.S. (Jeffrey), Brill, M.J.E. (Margreke J.E.), Dongen, E.H.P.A. (Eric) van, Knibbe, C.A.J. (Catherijne), Ramshorst, B. (Bert) van, van Rongen, A. (Anne), Vaughns, J.D. (Janelle D.), Välitalo, P.A.J. (Pyry A. J.)   +8 more
core   +4 more sources

An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 375-380, February 2026.
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered ...
Joseph Piscitelli, Micaela B. Reddy, Lance Wollenberg, Laurence Del Frari, Jason Gong, Kyle Matschke, Jason H. Williams   +6 more
wiley   +1 more source

Determination and Disposition of the Aromatase Inhibitor Exemestane in CYP3A-Deficient Mice

Molecules
Exemestane, a steroidal aromatase inhibitor prescribed for post-menopausal women with estrogen receptor-positive breast cancer, is associated with debilitating musculoskeletal side effects and exhibits considerable interindividual variability in systemic
Hanieh Taheri, Eman Ahmed, Peng Hu, Alex Sparreboom, Shuiying Hu   +4 more
doaj   +1 more source

CYTOCHROME P450 3A13 AND ENDOTHELIN JOINTLY MEDIATE DUCTUS ARTERIOSUS CONSTRICTION TO OXYGEN IN MICE [PDF]

, 2011
The fetal ductus arteriosus (DA) contracts to oxygen, and this feature, maturing through gestation, is considered important for its closure at birth.
Angeloni D, Baragatti B, Ciofini E, Coceani F., Luin S, Nencioni S, Ottaviano V, Pagni E, Paolicchi A, Ratto GM, Scebba F, Sodini D   +11 more
core   +1 more source

Induction of hepatic CYP3A4 expression by cholesterol and cholic acid: Alterations of gene expression, microsomal activity, and pharmacokinetics

Pharmacology Research & Perspectives
Human cytochrome P450 3A4 (CYP3A4) is a drug‐metabolizing enzyme that is abundantly expressed in the liver and intestine. It is an important issue whether compounds of interest affect the expression of CYP3A4 because more than 30% of commercially ...
Genki Minegishi, Yuka Kobayashi, Mayu Fujikura, Ayane Sano, Yasuhiro Kazuki, Kaoru Kobayashi   +5 more
doaj   +1 more source